Drug intelligence / Profile preview

KJ16001

Development stage: Preclinical
Lead developer: Kukje Pharm
Modality: Small Molecules
Administration: Ophthalmic

Overview

KJ16001 (also known as KSR-001) is a small molecule therapeutic candidate being developed by Kukje Pharm for the treatment of ophthalmic diseases, specifically dry eye syndrome. It is classified as an "improved/modified new drug" (incrementally modified drug), which typically refers to a new formulation, salt, or derivative of an existing active pharmaceutical ingredient intended to enhance efficacy, safety, or patient convenience. As of recent pipeline updates, the program is in the discovery research stage.

Beyond the preview

Go deeper on KJ16001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ16001.

Explore the full profile